Guggenheim Capital’s Insys Therapeutics, Inc. INSY Stock Holding History

Guggenheim Capital’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-149,777	Closed	-$2.4M	–	2968
2016 Q1	$2.4M	Sell	149,777 -30,767	-17%	-$584K	0.01%	1453
2015 Q4	$5.17M	Sell	180,544 -33,280	-16%	-$922K	0.02%	997
2015 Q3	$6.08M	Buy	213,824 +11,737	+6%	+$432K	0.02%	946
2015 Q2	$7.26M	Sell	202,087 -9,933	-5%	-$309K	0.02%	987
2015 Q1	$6.16M	Buy	212,020 +29,024	+16%	+$768K	0.01%	1066
2014 Q4	$3.86M	Buy	182,996 +10,312	+6%	+$204K	0.01%	1271
2014 Q3	$3.35M	Sell	172,684 -23,596	-12%	-$371K	0.01%	1411
2014 Q2	$3.06M	Buy	+196,280	New	+$3.17M	0.01%	1483
2013 Q4	–	Sell	-128,172	Closed	-$1.5M	–	3298
2013 Q3	$1.5M	Buy	+128,172	New	+$1.05M	0.01%	1827

Other funds holding INSY

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FHAM

Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GAM

Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Guggenheim Capital's INSY Position: Q2 2016 in Review

Guggenheim Capital sold out of Insys Therapeutics, Inc. (INSY) in Q2 2016, closing a stake of 149,777 shares — an estimated $2.4M sold.

Guggenheim Capital first reported a position in INSY in Q3 2013 and held it in 9 quarters. The position peaked at $7.26M in Q2 2015. 124 funds tracked by Wall St. Rank hold INSY as of Q2 2016.

Guggenheim Capital reported no remaining Insys Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
Guggenheim Capital sold 149,777 Insys Therapeutics, Inc. shares in Q2 2016, an estimated $2.4M.
Guggenheim Capital first reported a position in Insys Therapeutics, Inc. in Q3 2013 and held it in 9 quarters.
Guggenheim Capital's Insys Therapeutics, Inc. position peaked at $7.26M in Q2 2015.
124 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2016.

Based on Guggenheim Capital's 13F filing for Q2 2016, filed 15 Aug 2016.